Skip to main content
. Author manuscript; available in PMC: 2010 Mar 24.
Published in final edited form as: Br J Cancer. 2009 Feb 24;100(6):932–940. doi: 10.1038/sj.bjc.6604938

Figure 1.

Figure 1

Cytotoxicity of P529 in PC-3 and HUVECs. (A) PC-3 cells treated with different doses of P529. The GI50 was determined to be 5–7 μM. (B) In HUVECs, 500nM of P529 in the presence of 100ng/ml VEGF significantly (P<0.001) reduces cell proliferation, 96h after administration of the drug.